EUCTR2014-005401-20-Outside-EU/EEA进行中（未招募）不适用
An Open-label, Multi-centre Study to Assess the Efficacy and Safety of Biostate® in Patients With von Willebrand's Disease (VWD)
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- CSL Limited
- 入组人数
- 23
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients who fulfill the following criteria are eligible for inclusion into this study:
- •a) Patients with a diagnosis VWD who require prophylactic therapy, have a non-surgery bleed, or are undergoing surgery.
- •b) Patients who would routinely receive a plasma derived FVIII/VWF product as treatment for their VWD.
- •c) Patients over 3 years of age and =14 kg.
- •Inclusion of children < 13 years of age into the surgical and non-surgical bleed arms of the study will be at the discretion of the Investigator. The Investigator will take into consideration the blood profile of the patient and the required blood draw volume, bearing in mind that 17 ml of blood
- •is to be drawn prior to each administration of Biostate® and that in accordance with the National Institute of Health Clinical Centre Guidelines, a paediatric blood draw should not exceed 3ml/kg, or 7ml/kg in a 6 week period.
- •d) Patients and/or their legally acceptable representative must give written informed consent to participate in the study and must understand the nature of the study and must be willing to comply with all protocol requirements.
- •In addition, patients receiving prophylactic therapy or being managed for elective surgery must also fulfill the following criterion:
- •e) Patients must have been vaccinated against hepatitis A and B (unless protective antibodies are present resulting from a previously experienced infection). Documentation of immunisation (or protective antibodies resulting from a previous infection) must be present at baseline.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 9
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 13
排除标准
- •The following patients are not eligible for inclusion into this study:
- •a) Patients with a known history of adverse drug reactions to factor VIII/VWF concentrates.
- •b) Patients with a known or suspected VWF or FVIII inhibitor.
- •c) Patients who are currently taking non-steroidal anti-inflammatory drugs (NSAIDs) which in the opinion of the Investigator would affect the efficacy and safety outcomes of the study.
- •d) Patients with evidence or a history within the previous 12 months of abuse of any drug substance, licit or illicit, which in the opinion of the Investigator may affect the ability of the patient to comply with all protocol requirements.
- •e) Patients who have within 90 days prior to the study screening visit, participated in a clinical study or used an investigational compound (eg. a new chemical entity not registered for clinical use), or who are planning to enter such a different study during the study period.
- •f) Patients who are suffering from an acute or chronic medical condition, other than VWD, which may, in the opinion of the Investigator, affect the conduct of the study.
- •g) Patients with a positive pregnancy test.
研究者
相似试验
进行中（未招募）
1 期
An Open-label, Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 weeks pegylated interferon alfa-2a 40 kD (PEGASYS®) Combination Therapy with Ribavirin (Copegus®) in Patients with Chronic Hepatitis C Genotype 2 or 3 Infection who Previously Have Relapsed After a Minimum of 12 Weeks and a Maximum of 24 Weeks of Therapy with pegylated interferon and Ribavirin - RelapCchronic hepatitis C (CHC) virus infection genotype 2 or 3 who responded during (i.e. had HCV-RNA < 50 IU/mL at the end of previous therapy), but relapsed after (i.e. had detectable HCV-RNA after the end of prior treatment) previous therapy with pegylated interferon and ribavirin given for at least 12 weeks and at most 24 weeks.EUCTR2006-003409-18-SESahlgrenska University Hospital, Östra100
进行中（未招募）
不适用
An Open-label, Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 weeks pegylated interferon alfa-2a 40 kD (PEGASYS®) Combination Therapy with Ribavirin (Copegus®) in Patients with Chronic Hepatitis C Genotype 2 or 3 Infection who Previously Have Relapsed After a Minimum of 12 Weeks and a Maximum of 24 Weeks of Therapy with pegylated interferon and Ribavirin - RelapCchronic hepatitis C (CHC) virus infection genotype 2 or 3 who responded during (i.e. had HCV-RNA < 50 IU/mL at the end of previous therapy), but relapsed after (i.e. had detectable HCV-RNA after the end of prior treatment) previous therapy with pegylated interferon and ribavirin given for at least 12 weeks and at most 24 weeks.MedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2006-003409-18-FIHUS100
进行中（未招募）
1 期
An Open-label, Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 weeks pegylated interferon alfa-2a 40 kD (PEGASYS®) Combination Therapy with Ribavirin (Copegus®) in Patients with Chronic Hepatitis C Genotype 2 or 3 Infection who Previously Have Relapsed After a Minimum of 12 Weeks and a Maximum of 24 Weeks of Therapy with pegylated interferon and Ribavirin - RelapCChronic hepatitis C (CHC) genotype 2 or 3 infection with previous response relapseEUCTR2006-003409-18-DKRelap-C study Steering Commitee100
进行中（未招募）
1 期
A Study to evaluate the effect and safety of experimental drugs ABT-493/ABT-530 in adults with Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)Hepatitis C Virus InfectionHuman Immunodeficiency Virus InfectionChronic Hepatitis CCompensated Cirrhosis and Non-cirrhoticsEUCTR2015-005577-20-PLAbbVie Deutschland GmbH & Co. KG160
进行中（未招募）
1 期
A Study to evaluate the effect and safety of experimental drugs ABT-493/ABT-530 in adults with Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)EUCTR2015-005577-20-DEAbbVie Deutschland GmbH & Co. KG160